Citations

Clear

3042 citation(s) found for "Kumar, S".

Utility of serum free light chain ratio in response definition in patients with multiple myeloma
Abdallah, Nadine , Kapoor, Prashant , Murray, David , Buadi, Francis K. , Dingli, David , Gertz, Morie A. , Hayman, Suzanne R. , Kourelis, Taxiarchis , Lacy, Martha Q. , Lust, John A., Muchtar, Eli , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Gertz, Morie A , Muchtar, E , Buadi, Francis K , Dingli, David , Dispenzieri, Angela , Go, Ronald S. , Gonsalves, Wilson I. , Leung, Nelson , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | January 24, 2020 | Volume: 4 | Issue: 2 | Pages: 322-326

10.1182/bloodadvances.2019001099 | PMID 31978213 Get It

Key PointsPatients with an abnormal sFLC ratio because of LC suppression have outcomes similar to those with a normal ratio. sFLC ratio has prognostic value in patients achieving CR who have an absence of clonal BMPCs assessed by MFC.
Timeliness of Initial Therapy in Multiple Myeloma: Trends and Factors Affecting Patient Care
Moustafa, Muhamad Alhaj , Bojanini, Leyla , Sher, Taimur , Vishnu, Prakash , Bodepudi, Srilekha, Shareef, Zan , Ahmed, Salman , Jani, Prachi, Paulus, Aneel , Grover, Ashna , Alegria, Victoria R., Ailawadhi, Meghna, Chanan‐Khan, Asher , Alhaj-Moustafa, Muhamad, Manochakian, Rami , Chanan-Khan, Asher, Vishnu, Prakash , Moustafa, Muhamad Alhaj , Paulus, Aneel , Kumar, Vivek , Roy, Vivek , Ailawadhi, Sikander

Mayo Clinic

JCO Oncology Practice | January 21, 2020 | Volume: 16 | Issue: 4 | Pages: e341-e349

10.1200/jop.19.00309 | PMID 32048939 Get It

Multiple myeloma (MM) treatment has advanced significantly over the last 2 decades. In most patients, the disease course has been altered from early fatality to chronic morbidity with multiple lines of treatment. The MM treatment paradigm has shifted toward treating patients before end-organ damage occurs. Thus, timeliness of treatment initiation in this era might improve patient outcomes. This is the first report to our knowledge analyzing disparities and trends in treatment timeliness of patients with MM using the National Cancer Database. Multiple factors affected the timing of treatment initiation in MM and disparities were found. We noted that initiation of treatment was delayed in women (odds ratio [OR], 1.15; 95% CI, 1.1 to 1.2) and blacks (OR, 1.21; 95% CI, 1.14 to 1.28; reference, whites) and in patients diagnosed in more recent years (2012-2015; OR, 1.15; 95% CI, 1.1 to 1.22; reference, 2004-2007). Patients were likely to start treatment earlier if they were age ≥ 80 years (OR, 0.83; 95% CI, 0.76 to 0.9; reference, age < 60 years), were uninsured (OR, 0.81; 95% CI, 0.72 to 0.91; reference, private insurance), had Medicaid (OR, 0.87; 95% CI, 0.79 to 0.95; reference, private insurance), were treated in a comprehensive community cancer program (OR, 0.7; 95% CI, 0.65 to 0.77; reference, community cancer program), lived in a location other than the US Northeast, or had a higher Charlson comorbidity score. Patient education and income levels did not affect time to treatment initiation. Particular aspects of these disparities could be explained by our current health care system and insurance rules, whereas others need to be investigated more deeply.
Association of Adverse Childhood Experiences with Glycemic Control and Lipids in Children with Type 1 Diabetes
Iqbal, Anoop Mohamed, Kumar, Seema, Hansen, Janet S., Heyrman, Mary, Spee, Rebecca, Lteif, Aida, Hansen, Janet, Hansen, Janet

Mayo Clinic

Children | January 20, 2020 | Volume: 7 | Issue: 1 | Pages: 8

10.3390/children7010008 | PMID 31963630 Get It

Adverse childhood experiences (ACE) have been associated with a greater prevalence of risky behaviors and chronic health conditions, such as diabetes in adulthood. While adolescents with risk taking behaviors experience worsening of diabetic metabolic control, it is yet to be determined whether glycemic management in children and adolescents is negatively and independently influenced by ACEs. This study examines the relationship between ACEs in children and adolescents with type 1 diabetes (T1DM) and glycemic control, BMI and lipids. For such children, we hypothesized that hemoglobin A1c (HbA1c) is positively correlated with ACE scores. Parents of children (age 2–18 years) with T1DM completed a validated ACE questionnaire. The associations between parent and child ACE score and HbA1c, lipids and BMI z-scores were assessed using linear regression. The prevalence of any ACE was 27.9% among children and 49.0% among parents. HbA1c was significantly higher in children who had exposure to three or more ACEs (β:0.63 (4.5 mmol/mol); p = 0.02), in those who had a parent exposed to four or more ACEs (β:0.87 (7.2 mmol/mol); p = 0.03), in children who had exposure to household incarceration (β:0.62 (4.4 mmol/mol); p = 0.05) and children who witnessed or had been victim of violence in the neighborhood (β:0.71 (5.4 mmol/mol); p = 0.02). ACEs were highly prevalent among children with T1DM and had a positive association with glycemic control.
Systematic Review and Meta-Analysis—Is there a Benefit in Using Neoadjuvant Systemic Chemotherapy for Locally Advanced Penile Squamous Cell Carcinoma?
Azizi, Mounsif , Aydın, Ahmet Murat , Hajiran, Ali , Kumar, Ambuj , Peyton, Charles C. , Minhas, Suks , Sonpavde, Guru , Chahoud, Jad , Pagliaro, Lance C. , Lai, Andrew, Necchi, Andrea , Spiess, Philippe E.

Mayo Clinic

Journal of Urology | January 13, 2020 | Volume: 203 | Issue: 6 | Pages: 1147-1155

10.1097/ju.0000000000000746 | PMID 31928407 Get It

Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017
Haagsma, Juanita A. , James, Spencer L , Castle, Chris D, Dingels, Zachary V, Fox, Jack T, Hamilton, Erin B, Lucchesi, Lydia R , Sylte, Dillon O , Adebayo, Oladimeji , Ahmadi, Alireza , Aichour, Miloud Taki Eddine, Alahdab, Fares , Al‐Raddadi, Rajaa , Alsharif, Ubai , Altirkawi, Khalid A , Anjomshoa, Mina, Appiah, Seth Christopher Yaw , Aremu, Olatunde , Arora, Amit , Assadi, Reza , Awasthi, Ashish , Quintanilla, Beatriz Paulina Ayala , Balalla, Shivanthi , Banstola, Amrit , Barker‐Collo, Suzanne , Bärnighausen, Till , Behzadifar, Meysam, Bennett, Derrick , Bhaumik, Soumyadeep , Bhutta, Zulfiqar A , Bijani, Ali , Borges, Guilherme , Borschmann, Rohan , Bose, Dipan, Bražinová, Alexandra, Campuzano, Julio César , Cárdenas, Rosario , Carvalho, Félix , Castañeda-Orjuela, Carlos A , Catalá-López, Ferrán , Choi, Jee-Young Jasmine , Christopher, Devasahayam Jesudas , Crowe, Christopher S. , Dalal, Koustuv , Leo, Diego De, Neve, Jan‐Walter De , Deribe, Kebede , Dessie, Getenet , deVeber, Gabrielle , Dharmaratne, Samath Dhamminda , Doan, Linh Phuong , Driscoll, Tim , El‐Khatib, Ziad , Ellingsen, Christian Lycke , Endries, Aman Yesuf , Faro, André , Fereshtehnejad, Seyed‐Mohammad , Fernandes, Eduarda , Fischer, Florian , Franklin, Richard C. , Fukumoto, Takeshi , Gezae, Kebede Embaye , Gill, Tiffany K, Goulart, Alessandra C. , Grada, Ayman , Guo, Yuming , Haghparast‐Bidgoli, Hassan , Haj‐Mirzaian, Arvin , Haj‐Mirzaian, Arya , Hamadeh, Randah R , Hassen, Hamid Yimam , Havmoeller, Rasmus, Henok, Andualem , Hı́jar, Martha, Hole, Michael K., Rad, Enayatollah Homaie , Hossain, Naznin , Hostiuc, Sorin , Igumbor, Ehimario , Irvani, Seyed Sina Naghibi , Islam, Sheikh Mohammed Shariful , Ivers, Rebecca , Jacobsen, Kathryn H. , Jahanmehr, Nader , Jakovljević, Mihajlo , Jha, Ravi Prakash , Shushtari, Zahra Jorjoran , Jozwiak, Jacek Jerzy , Jürisson, Mikk , Kalani, Rizwan, Kasaeian, Amir , Kelbore, Abraham Getachew , Kengne, André Pascal , Khader, Yousef , Khafaie, Morteza Abdullatif , Khalid, Nauman , Khan, Ejaz Ahmad , Kiadaliri, Ali , Kim, Yun Jin , Kısa, Adnan , Defo, Barthélémy Kuate , Biçer, Burcu Küçük , Kumar, Manasi , Lalloo, Ratilal , Lam, Hilton Y. , Lami, Faris , Leasher, Janet L , Li, Shanshan , Linn, Shai , Lunevičius, Raimundas , Machado, Flávia Ribeiro , Razek, Hassan Magdy Abd El , Razek, Muhammed Magdy Abd El, Mahotra, Narayan Bahadur , Majdán, Marek , Majeed, Azeem , Malekzadeh, Reza, Malik, Manzoor Ahmad , Manda, Ana-Laura, Massenburg, Benjamin B. , Maulik, Pallab K , Meheretu, Hailemariam Abiy Alemu , Mehndiratta, Man Mohan, Mendoza, Walter, Mengesha, Melkamu Merid , Meretoja, Tuomo J , Meretoja, Atte , Miazgowski, Tomasz , Miller, Ted R. , Mini, GK , Мirrakhimov, Erkin М , Moazen, Babak , Mezerji, Naser Mohammad Gholi, Mohammadibakhsh, Roghayeh , Mohammed, Shafiu , Molokhia, Mariam , Monasta, Lorenzo , Mondello, Stefania , Montero-Zamora, Pablo A. , Moodley, Yoshan , Moosazadeh, Mahmood , Moradi, Ghobad , Morawska, Lídia , Velásquez, Ilais Moreno , Moschos, Marilita M. , Mousavi, Seyyed Meysam , Murthy, Srinivas , Musa, Kamarul Imran , Naik, Gurudatta , Nangia, Vinay, Nascimento, Bruno Ramos , Ndwandwe, Duduzile , Negoi, Ionuţ , Nguyen, Son Hoang , Nguyen, Long Hoang , Ningrum, Dina Nur Anggraini , Nirayo, Yirga Legesse, Ofori‐Asenso, Richard , Ogbo, Felix Akpojene , Oladimeji, Olanrewaju , Olagunju, Andrew T , Olagunju, Tinuke O , Orpana, Heather , Otstavnov, Stanislav S , Mahesh, P A , Pakhalé, Smita , Park, Eun‐Kee , Pesudovs, Konrad , Polinder, Suzanne , Prakash, Swayam , Rafay, Anwar, Rafiei, Alireza , Rahimi, Siavash , Rahimi‐Movaghar, Vafa , Rahman, Muhammad Aziz , Kumar, Rajesh , Ramezanzadeh, Kiana, Rawaf, David Laith , Renzaho, André M. N. , Resnikoff, Serge , Roever, Leonardo , Sabde, Yogesh , Saddik, Basema , Salamati, Payman , Salimi, Yahya , Salz, Inbal, Samy, Abdallah M , Sanabria, Juan , Sànchez-Riera, Lídia , Santric-Milicevic, Milena M , Satpathy, Maheswar , Sawhney, Monika, Sawyer, Susan M. , Şaylan, Mete , Schwebel, David C. , Seedat, Soraya , Shaikh, Masood Ali, Shams-Beyranvand, Mehran , Shamsizadeh, Morteza , Sharif-Alhoseini, Mahdi , Sheikh, Aziz , Shigematsu, Mika, Shiri, Rahman , Shiue, Ivy , Silva, João Pedro , Sinha, Dhirendra Narain , Filho, Adauto Martins Soares , Soriano, Joan B. , Soshnikov, Sergey , Soyiri, Ireneous N , Starodubov, Vladimir I., Stein, Dan J. , Sufiyan, Mu’awiyyah Babale , Sunshine, Jacob E. , Sykes, Bryan L. , Tabarés‐Seisdedos, Rafael , Tabb, Karen M. , Tessema, Gizachew Assefa , Thakur, Jarnail Singh , Car, Lorainne Tudor , Uzochukwu, Benjamin, Valdéz, Pascual , Varavikova, Elena A. , Vasconcelos, Ana Maria Nogales , Violante, Francesco Saverio , Waheed, Yasir , Wang, Yuan‐Pang , Wijeratne, Tissa , Yadav, Priyanka , Yano, Yuichiro , Yenesew, Muluken Azage, Yisma, Engida , Younis, Mustafa Z , Zafar, Shamsa , Zaman, Sojib Bin , Zodpey, Sanjay , Hay, Simon I , Mokdad, Ali H. , Vos, Theo , Khubchandani, Jagdish , Padrón‐Monedero, Alicia , Wijeratne, T , Stein, Dan J , Islam, Sheikh Mohammed Shariful , Assadi, Reza , Rahman, Muhammad Aziz , Liu, Zichen, Roberts, Nicholas L S , Ahmed, Muktar Beshir , Alghnam, Suliman Abdullah , Aljunid, Syed Mohamed , Antonio, Carl Abelardo T. , Asayesh, Hamid , Bazargan‐Hejazi, Shahrzad , Bedi, Neeraj , Behzadifar, Masoud , Behzadifar, Meysam, Benjet, Corina L. , Benseñor, Isabela M. , Boufous, Soufiane , Carrero, Juan Jesús , Daryani, Ahmad , Daviţoiu, Dragoş Virgil , Degenhardt, Louisa J , Dolan, Kate A , Dubey, Manisha , Zaki, Maysaa El Sayed , Eskandarieh, Sharareh , Filip, Irina , Gill, Tiffany K. , Gupta, Rahul, Hamidi, Samer , Haro, Josep María , Hassankhani, Hadi , Hendrie, Delia V. , Hı́jar, Martha , Hu, Guoqing , Ilesanmi, Olayinka Stephen , Jayatilleke, Achala Upendra , Jonas, Jost B , Kabir, Ali , Kalani, Rizwan, Khoja, Abdullah T , Kim, Young‐Eun , Kim, Daniel , Koyanagi, Ai , Lansingh, Van Charles , Malta, Déborah Carvalho , Mansournia, Mohammad Alì , Melese, Addisu Dagnaw , Meštrović, Tomislav , Moradi‐Lakeh, Maziar , Morrison, Shane D. , Najafi, Farid , Nguyen, Trang Huyen , Nguyen, Huong Lan Thi , Oh, In‐Hwan , Olivares, Pedro Rufino , Patton, George , Phillips, Michael , Radfar, Amir , Rawaf, Salman , Rezaeian, Shahab , Ronfani, Luca , Roshandel, Gholamreza , Saxena, Sonia , Schneider, Ione Jayce Ceola , Sepanlou, Sadaf Ghajarieh , Shen, Jiabin , Singh, Jasvinder A. , Стародубов, В. И. , Stokes, Mark Andrew , Tehrani‐Banihashemi, Arash , Tran, Khanh Bao , Tran, Bach Xuan , Uthman, Olalekan Abdulrahman , Venketasubramanian, Narayanaswamy , Vlassov, Vasily , Winkler, Andrea Sylvia , Azage, Muluken , YIP, PAUL S. F. , Yonemoto, Naohiro , Yu, Chuanhua , Zaidi, Zoubida , Zamani, Mohammad , Zhao, Yong , Lopez, Alan D , Olagunju, Andrew T , Alahdab, Fares

Mayo Clinic

Injury Prevention | January 9, 2020 | Volume: 26 | Issue: Suppl 2 | Pages: i12-i26

10.1136/injuryprev-2019-043296 | PMID 31915273 Get It

Background The epidemiological transition of non-communicable diseases replacing infectious diseases as the main contributors to disease burden has been well documented in global health literature. Less focus, however, has been given to the relationship between sociodemographic changes and injury. The aim of this study was to examine the association between disability-adjusted life years (DALYs) from injury for 195 countries and territories at different levels along the development spectrum between 1990 and 2017 based on the Global Burden of Disease (GBD) 2017 estimates. Methods Injury mortality was estimated using the GBD mortality database, corrections for garbage coding and CODEm—the cause of death ensemble modelling tool. Morbidity estimation was based on surveys and inpatient and outpatient data sets for 30 cause-of-injury with 47 nature-of-injury categories each. The Socio-demographic Index (SDI) is a composite indicator that includes lagged income per capita, average educational attainment over age 15 years and total fertility rate. Results For many causes of injury, age-standardised DALY rates declined with increasing SDI, although road injury, interpersonal violence and self-harm did not follow this pattern. Particularly for self-harm opposing patterns were observed in regions with similar SDI levels. For road injuries, this effect was less pronounced. Conclusions The overall global pattern is that of declining injury burden with increasing SDI. However, not all injuries follow this pattern, which suggests multiple underlying mechanisms influencing injury DALYs. There is a need for a detailed understanding of these patterns to help to inform national and global efforts to address injury-related health outcomes across the development spectrum.
Venous thromboembolism risk with contemporary lenalidomide‐based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta‐analysis
Chakraborty, Rajshekhar , Riaz, Irbaz Bin , Malik, Saad Ullah , Marneni, Naimisha , Garcia, Alex Mejia, Anwer, Faiz , Kumar, Shaji , Murad, M. Hassan , Majhail, Navneet S. , Bin Riaz, Irbaz, Kumar, Shaji K , Majhail, Navneet S , Murad, M Hassan , Chakraborty, Rajshekhar , Riaz, Irbaz B , Anwer, Faiz , Khorana, Alok A. , Rajkumar, S. Vincent , Wang, Zhen , Khan, Safi U.

Mayo Clinic

Cancer | January 8, 2020 | Volume: 126 | Issue: 8 | Pages: 1640-1650

10.1002/cncr.32682 | PMID 31913498 Get It

Background Thromboprophylaxis is routinely used with lenalidomide‐based regimens in multiple myeloma because of a substantial risk of venous thromboembolism (VTE). However, little is known about the incidence of VTE with contemporary lenalidomide‐based regimens. The objective of the current study was to estimate the incidence of VTE despite thromboprophylaxis with currently used lenalidomide‐based regimens in patients with myeloma. Methods The Ovid MEDLINE, Embase, and Cochrane databases were queried from study inception to January 2019 for keywords to cover the following concepts: “lenalidomide,” “venous thromboembolism,” and “multiple myeloma.” Phase 1, 2, and 3 clinical trials evaluating lenalidomide‐based regimens with thromboprophylaxis were included. The pooled incidence rate of VTE was estimated using a random‐effects model. Results The search generated 1372 citations, with 51 clinical trials and 9069 patients included for analysis. The most common thromboprophylaxis agents were aspirin, low‐molecular‐weight heparin or warfarin, administered either per risk‐stratification or at investigators' discretion. The pooled incidence of VTE in trials of patients who had newly diagnosed and relapsed/refractory myeloma was 6.2% (95% CI, 5.4%‐7.1%) over median treatment durations ranging from 2 to 34 cycles, which translated into 1.2 VTE events per 100 patient‐cycles (95% CI, 0.9‐1.7 VTE events per 100 patient‐cycles). Among contemporary regimens, the risk of VTE was low with combined lenalidomide and low‐dose dexamethasone (0.2 [95% CI, 0.1‐0.6] events/100 patient‐cycles) and lenalidomide maintenance (0.0 [95% CI, 0.0‐0.7] events per 100 patient‐cycles). VTE risk was higher with combined lenalidomide and low‐dose dexamethasone plus proteasome inhibitors (1.3 [95% CI, 0.7‐2.3] events per 100 patient‐cycles). Conclusions Despite adequate thromboprophylaxis, lenalidomide‐based regimens have a substantial risk of VTE in controlled clinical trial settings. Further studies are needed on new thromboprophylaxis strategies with regimens that have a high VTE risk.
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Gray, Robert J. , Chen, Alice P. , Patton, David R. , Mitchell, Edith P. , Iafrate, A. John , Sklar, Jeffrey , Harris, Lyndsay N. , Rubinstein, Larry , Routbort, Mark, Coffey, Brent , Fu, Tony, Little, Richard F. , Marinucci, Donna M. , Catalano, Robert B., Magnan, Rick, Kibbe, Warren A. , Weil, Carol J. , Tricoli, James V. , Kumar, Shaji , Lih, Chih‐Jian, McCaskill‐Stevens, Worta , Takebe, Naoko, Datta, Vivekananda, Arteaga, Carlos L. , Abrams, Jeffrey S. , Comis, Robert L., O’Dwyer, Peter J , Conley, Barbara A. , Team, for the NCI-MATCH, Gray, Robert J , Patton, David R , Flaherty, Keith T. , Li, Shuli , Hamilton, Stanley R. , Williams, P. Mickey , McShane, Lisa M. , Sims, David J, Zwiebel, James A. , Alexander, Brian M. , Schwartz, Gary K. , Meric‐Bernstam, Funda , Caimi, Paolo F. , Takebe, Naoko , O’Dwyer, Peter J. , Team, for the NCI-MATCH, Rubinstein, Larry V

Mayo Clinic

JNCI: Journal of the National Cancer Institute | January 6, 2020 | Volume: 112 | Issue: 10 | Pages: 1021-1029

10.1093/jnci/djz245 | PMID 31922567 Get It

Abstract Background The proportion of tumors of various histologies that may respond to drugs targeted to molecular alterations is unknown. NCI-MATCH, a collaboration between ECOG-ACRIN Cancer Research Group and the National Cancer Institute, was initiated to find efficacy signals by matching patients with refractory malignancies to treatment targeted to potential tumor molecular drivers regardless of cancer histology. Methods Trial development required assumptions about molecular target prevalence, accrual rates, treatment eligibility, and enrollment rates as well as consideration of logistical requirements. Central tumor profiling was performed with an investigational next-generation DNA–targeted sequencing assay of alterations in 143 genes, and protein expression of protein expression of phosphatase and tensin homolog, mutL homolog 1, mutS homolog 2, and RB transcriptional corepressor 1. Treatments were allocated with a validated computational platform (MATCHBOX). A preplanned interim analysis evaluated assumptions and feasibility in this novel trial. Results At interim analysis, accrual was robust, tumor biopsies were safe (&lt;1% severe events), and profiling success was 87.3%. Actionable molecular alteration frequency met expectations, but assignment and enrollment lagged due to histology exclusions and mismatch of resources to demand. To address this lag, we revised estimates of mutation frequencies, increased screening sample size, added treatments, and improved assay throughput and efficiency (93.9% completion and 14-day turnaround). Conclusions The experiences in the design and implementation of the NCI-MATCH trial suggest that profiling from fresh tumor biopsies and assigning treatment can be performed efficiently in a large national network trial. The success of such trials necessitates a broad screening approach and many treatment options easily accessible to patients.
Cell cycle regulation and hematologic malignancies
Dai, Yun , Jin, Fengyan , Wu, Wei , Kumar, Shaji , Dai, Yun

Mayo Clinic

Blood Science | January 2, 2020 | Volume: 1 | Issue: 1 | Pages: 34-43

10.1097/bs9.0000000000000009 | PMID 35402801 Get It

Abstract A complex network precisely regulates the cell cycle through the G1, S, G2, and M phases and is the basis for cell division under physiological and pathological conditions. On the one hand, the transition from one phase to another as well as the progression within each phase is driven by the specific cyclin-dependent kinases (CDKs; e.g., CDK1, CDK2, CDK4, CDK6, and CDK7), together with their exclusive partner cyclins (e.g., cyclin A1, B1, D1–3, and E1). On the other hand, these phases are negatively regulated by endogenous CDK inhibitors such as p16ink4a, p18ink4c, p19ink4d, p21cip1, and p27kip1. In addition, several checkpoints control the commitment of cells to replicate DNA and undergo mitosis, thereby avoiding the passage of genomic errors to daughter cells. CDKs are often constitutively activated in cancer, which is characterized by the uncontrolled proliferation of transformed cells, due to genetic and epigenetic abnormalities in the genes involved in the cell cycle. Moreover, several oncogenes and defective tumor suppressors promote malignant changes by stimulating cell cycle entry and progression or disrupting DNA damage responses, including the cell cycle checkpoints, DNA repair mechanisms, and apoptosis. Thus, genes or proteins related to cell cycle regulation remain the main targets of interest in the treatment of various cancer types, including hematologic malignancies. In this context, advances in the understanding of the cell cycle regulatory machinery provide a basis for the development of novel therapeutic approaches. The present article summarizes the pathways as well as their genetic and epigenetic alterations that regulate the cell cycle; moreover, it discusses the various approved or potential therapeutic targets associated with the cell cycle, focusing on hematologic malignancies.
Methemoglobinemia in Transplant Recipient Patients: Future of Dapsone as Pneumocystis carinii Pneumonia Prophylaxis
Sahu, Kamal Kant , Lal, Amos , George, Susan, Lal, Amos , Mishra, Ajay Kumar

Mayo Clinic

Progress in Transplantation | January 2, 2020 | Volume: 30 | Issue: 1 | Pages: 71-72

10.1177/1526924819893316 | PMID 31894730 Get It

Revisiting Criteria for Psychosis in Alzheimer’s Disease and Related Dementias: Toward Better Phenotypic Classification and Biomarker Research
Ismail, Zahinoor , Youakim, James M. , Kumar, Sanjeev , Núñez, Nicolás A. , Darby, R. Ryan , D’Antonio, Fabrizia , Lena, Carlo de , McGeown, William J. , Ravona, Ramit, Rasmussen, J , Bell, J. Simon , Wang, Huali , Bruneau, Marie‐Andrée , Agüera-Ortíz, Luis , Lyketsos, Constantine G. , Sano, Mary , Devanand, Davangere P. , Ballard, Clive , Nunez, Nicolas, Ballard, Clive , Fischer, Corinne Eleanor , Creese, Byron , Vita, Antonella Di , Panegyres, Peter K. , Lanctôt, Krista L. , Cummings, Jeffrey L. , Jeste, Dilip V. , Sweet, Robert A.

Mayo Clinic

Journal of Alzheimer’s Disease | December 27, 2019 | Volume: 73 | Issue: 3 | Pages: 1143-1156

10.3233/jad-190828 | PMID 31884469 Get It

Background: Psychotic symptoms are common in Alzheimer’s disease (AD) and related neurodegenerative disorders and are associated with more rapid disease progression and increased mortality. It is unclear to what degree existing criteria are utilized in clinical research and practice. Objective: To establish research criteria for the diagnosis of psychosis in AD. Methods: The International Society to Advance Alzheimer’s Research and Treatment (ISTAART) Neuropsychiatric Symptoms (NPS) Professional Interest Area (PIA) psychosis subgroup reviewed existing criteria for psychosis in AD and related dementias. Through a series of in person and on-line meetings, a priority checklist was devised to capture features necessary for current research and clinical needs. PubMed, Medline and other relevant databases were searched for relevant criteria. Results: Consensus identified three sets of criteria suitable for review including those of Jeste and Finkel, Lyketsos, and the Diagnostic and Statistical Manual for Mental Disorders, 5th edition. It was concluded that existing criteria could be augmented by including a more specific differentiation between delusions and hallucinations, address overlap with related conditions (agitation in particular), adding the possibility of symptoms emerging in the preclinical and prodromal phases, and building on developing research in disease biomarkers. Conclusion: We propose criteria, developed to improve phenotypic classification of psychosis in AD, and advance the research agenda in the field to improve epidemiological, biomarker, and genetics research in the field. These criteria serve as a complement to the International Psychogeriatric Association criteria for psychosis in neurocognitive disorders.